Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 15/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25370048 | 0.83 | DDB1 (0.37) | DDB1CRBNCHRM4CHRM5CHRM1 | |
| SCHEMBL24207759 | 0.83 | DDB1 (0.37) | DDB1CRBNCHRM4CHRM5CHRM1 | |
| SCHEMBL32672139 | 0.81 | CRBN (0.58) | DDB1CRBN | |
| SCHEMBL26100228 | 0.81 | CRBN (0.58) | DDB1CRBN | |
| SCHEMBL25339735 | 0.78 | DDB1 (0.44) | DDB1CRBN | |
| SCHEMBL24204484 | 0.78 | DDB1 (0.44) | DDB1CRBN | |
| SCHEMBL32674370 | 0.76 | CRBN (0.46) | DDB1CRBNCHRM2 | |
| SCHEMBL30262848 | 0.76 | CRBN (0.59) | DDB1CRBNCHRM2 | |
| SCHEMBL29223457 | 0.76 | CRBN (0.59) | DDB1CRBNCHRM2 | |
| SCHEMBL29223460 | 0.76 | CRBN (0.59) | DDB1CRBNCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | TRIANA BIOMEDICINES, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260042752-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042752-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | ALK, NTRK1, NTRK3 | DDB1 4032/4885CRBN 2191/4885CHRM4 3775/4885 |
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | ALK, NTRK3, NTRK1 | DDB1 4568/4885CRBN 626/4885CHRM4 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.